Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
OwnerKrisztina M. Zsebo, Robert A. Bosselman +2inventors
InventorsKrisztina M. Zsebo, Robert A. Bosselman, Sidney V. Suggs, Francis H. Martin
Life of this patent
Estimating the term…
Abstract
Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.
Claims12
A method for increasing the number of early hematopoietic progenitor cells in the peripheral blood of a human, the method comprising the step of administering to the human, a hematopoietically effective amount of a human stem cell factor polypeptide, the stem cell factor polypeptide selected from the group consisting of amino acids 1-162, 1-164, and 1-165 as set out in FIG. 15C, said polypeptide optionally consisting of an N-terminal methionine.
A method for increasing the number of early hematopoietic progenitor cells in the peripheral blood of a human, the method comprising the step of administering to the human, a hematopoietically effective amount of a human stem cell factor polypeptide, the stem cell factor polypeptide selected from the group consisting of amino acids 1-100, 1-110, 1-120, 1-123, 1-127, 1-130, 1-133, 1-137, 1-141, 1-145, 1-148, 1-152, 1-156, 1-157, 1-158, 1-159, 1-160, 1-161, 1-163, 1-166, 1-168, 1-173, 1-178, 2-164, 2-165, 5-164, 11-164, 1-180, 1-183, 1-185, 1-188, 1-189, 1-220, and 1-248 as set out in FIGS. 42A-C, said polypeptide optionally consisting of an N-terminal methionine.
A method for increasing the number of early hematopoietic progenitor cells in theperipheral blood of a human, the method comprising the step of administering to the human, a hematopoietically effective amount of a human stem cell factor polypeptide, the stem cell factor polypeptide selected from the group consisting of amino acids 1-152, 1-157, 1-160, 1-161, and 1-220 as set out in FIGS. 44A-C, said polypeptide optionally consisting of an N-terminal methionine.
A method for providing early hematopoietic progenitor cells to a human in need thereof, the method comprising the steps of:
- a) obtaining early hematopoietic progenitor cells from a human donor;
- b) exposing the early hematopoietic progenitor cells obtained in step a) to a hematopoietically effective amount of a human stem cell factor polypeptide, the stem cell factor polypeptide selected from the group consisting of amino acids 1-162, 1-164 and 1-165 as set out in FIG. 15C, said polypeptide optionally consisting of an N-terminal methionine, thereby increasing the number of hematopoietic cells;
- and
- c) administering to said human the early hematopoietic progenitor cells obtained in step b).
A method for providing early hematopoietic progenitor cells to a human in need thereof, the method comprising the steps of:
- a) obtaining early hematopoietic progenitor cells from a human donor;
- b) exposing the early hematopoietic progenitor cells obtained in step a) to a hematopoietically effective amount of a human stem cell factor polypeptide, the stem cell factor polypeptide selected from the group consisting of amino acids 1-100, 1-110, 1-120, 1-123, 1-127, 1-130, 1-133, 1-137, 1-141, 1-145, 1-148, 1-152, 1-156, 1-157, 1-158, 1-159, 1-160, 1-161, 1-163, 1-166, 1-168, 1-173, 1-178, 2-164, 2-165, 5-164, 11-164, 1-180, 1-183, 1-185, 1-188, 1-189, 1-220, and 1-248 as set out in FIGS. 42A-C, said polypeptide optionally consisting of an N-terminal methionine, thereby increasing the number of hematopoietic progenitor cells;
- and
- c) administering to said human the early hematopoietic progenitor cells obtained in step b).
A method for providing early hematopoietic progenitor cells to a human in need thereof, the method comprising the steps of:
- a) obtaining early hematopoietic progenitor cells from a human donor;
- b) exposing the early hematopoietic progenitor cells obtained in step a) to a hematopoietically effective amount of a human stem cell factor polypeptide, the stem cell factor polypeptide selected from the group consisting of amino acids 1-152, 1-157, 1-160, 1-161, and 1-220 as set out in FIGS. 44A-C, said polypeptide optionally consisting of an N-terminal methionine, thereby increasing the number of hematopoietic progenitor cells;
- and
- c) administering to said human the early hematopoietic progenitor cells obtained in step b).
Dependencies are inferred from the claim text.